JP5242391B2 - Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物 - Google Patents

Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物 Download PDF

Info

Publication number
JP5242391B2
JP5242391B2 JP2008522796A JP2008522796A JP5242391B2 JP 5242391 B2 JP5242391 B2 JP 5242391B2 JP 2008522796 A JP2008522796 A JP 2008522796A JP 2008522796 A JP2008522796 A JP 2008522796A JP 5242391 B2 JP5242391 B2 JP 5242391B2
Authority
JP
Japan
Prior art keywords
methyl
pyridin
quinolin
ppm
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008522796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502780A (ja
JP2009502780A5 (cg-RX-API-DMAC7.html
Inventor
スリーニバサ・レディ・ムンドラ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2009502780A publication Critical patent/JP2009502780A/ja
Publication of JP2009502780A5 publication Critical patent/JP2009502780A5/ja
Application granted granted Critical
Publication of JP5242391B2 publication Critical patent/JP5242391B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2008522796A 2005-07-22 2006-06-29 Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物 Expired - Fee Related JP5242391B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70164105P 2005-07-22 2005-07-22
US60/701,641 2005-07-22
PCT/US2006/025377 WO2007018818A1 (en) 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor

Publications (3)

Publication Number Publication Date
JP2009502780A JP2009502780A (ja) 2009-01-29
JP2009502780A5 JP2009502780A5 (cg-RX-API-DMAC7.html) 2009-08-20
JP5242391B2 true JP5242391B2 (ja) 2013-07-24

Family

ID=37450942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522796A Expired - Fee Related JP5242391B2 (ja) 2005-07-22 2006-06-29 Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物

Country Status (16)

Country Link
US (1) US7872020B2 (cg-RX-API-DMAC7.html)
EP (1) EP1910370B1 (cg-RX-API-DMAC7.html)
JP (1) JP5242391B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0613639A2 (cg-RX-API-DMAC7.html)
CA (1) CA2616196C (cg-RX-API-DMAC7.html)
DK (1) DK1910370T3 (cg-RX-API-DMAC7.html)
ES (1) ES2542425T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150474T1 (cg-RX-API-DMAC7.html)
HU (1) HUE025209T2 (cg-RX-API-DMAC7.html)
IL (1) IL188181A (cg-RX-API-DMAC7.html)
MX (1) MX2008001020A (cg-RX-API-DMAC7.html)
PL (1) PL1910370T3 (cg-RX-API-DMAC7.html)
PT (1) PT1910370E (cg-RX-API-DMAC7.html)
RS (1) RS53999B1 (cg-RX-API-DMAC7.html)
SI (1) SI1910370T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007018818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
RU2612958C2 (ru) 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
EP2917365B1 (en) 2012-11-12 2020-03-11 Institució Catalana de Recerca i Estudis Avançats Methods and kits for the prognosis of colorectal cancer
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EP3277673B1 (en) 2015-04-01 2022-05-04 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
US10450318B2 (en) 2015-12-15 2019-10-22 Bristol-Myers Squibb Company CXCR4 receptor antagonists
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10604528B2 (en) 2016-07-07 2020-03-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Galunisertib crystalline form, preparation method thereof and use thereof
WO2018068759A1 (zh) 2016-10-14 2018-04-19 江苏恒瑞医药股份有限公司 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2018165979A1 (zh) * 2017-03-17 2018-09-20 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物
WO2018170724A1 (zh) 2017-03-21 2018-09-27 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶,其制备方法和药物组合物
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN115282280A (zh) * 2022-08-12 2022-11-04 中国科学技术大学 TGF-β1信号抑制剂的新用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1397364T1 (sl) * 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
EP1567528A1 (en) * 2002-11-21 2005-08-31 Eli Lilly And Company Mixed lineage kinase modulators
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles

Also Published As

Publication number Publication date
RS53999B1 (sr) 2015-10-30
BRPI0613639A2 (pt) 2012-02-22
JP2009502780A (ja) 2009-01-29
CA2616196A1 (en) 2007-02-15
EP1910370B1 (en) 2015-04-22
HUE025209T2 (en) 2016-03-29
ES2542425T3 (es) 2015-08-05
MX2008001020A (es) 2008-03-25
PT1910370E (pt) 2015-06-30
EP1910370A1 (en) 2008-04-16
SI1910370T1 (sl) 2015-06-30
CA2616196C (en) 2012-08-21
IL188181A0 (en) 2008-03-20
US7872020B2 (en) 2011-01-18
HRP20150474T1 (xx) 2015-06-05
DK1910370T3 (en) 2015-06-08
WO2007018818A1 (en) 2007-02-15
US20100120854A1 (en) 2010-05-13
IL188181A (en) 2014-05-28
PL1910370T3 (pl) 2015-09-30

Similar Documents

Publication Publication Date Title
JP2009502780A (ja) Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物
JP5043432B2 (ja) ピラゾロ−キナゾリン誘導体、その製造方法、およびキナーゼ阻害剤としてのその使用
EP1177185B1 (en) 4, 5, 6, 7-tetrahydroindazole derivatives as antitumor agents
EP4667458A1 (en) Pharmaceutical composition for treatment of cancer, comprising sos1 inhibitor and anticancer drug
CA2407573C (en) Imidazopyridine derivatives
EP3381896B1 (en) Biphenyl compound or salt thereof
EP4389738A1 (en) Sos1 inhibitor and use thereof
CN109311894B (zh) 作为激酶抑制剂的n-(取代的-苯基)-磺酰胺衍生物
US6403588B1 (en) Imidazopyridine derivatives
JP6430512B2 (ja) リジン特異的デメチラーゼ−1の阻害剤
KR20180048635A (ko) Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
EA029515B1 (ru) Пиразолопирролидиновые производные и их применение в лечении заболеваний
TW200804391A (en) Azepine inhibitors of janus kinases
SK2402002A3 (en) Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives, method for producing thereof and pharmaceutical composition containing the same
TW200846001A (en) Therapeutic compounds
JP2015520186A (ja) 増殖性疾患の治療にキナーゼ阻害剤として有用なジヒドロナフチリジン及び関連化合物
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
JP2007534710A (ja) 置換フェニルアミノピリミジン化合物
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
CN108349947A (zh) 四氢吲唑及其医药用途
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
CN118359627A (zh) 具有四环并环结构的mta协同性prmt5抑制剂化合物
WO2014020531A1 (en) Imidazo[1,2-b]pyridazin-6-amine derivatives as kinase jak-2 inhibitors
JP2024528073A (ja) 有機ピリジン-ピラゾール化合物及びその使用
WO2020200154A1 (zh) 一类噻吩并氮杂环类化合物、制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130204

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130403

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160412

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5242391

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees